WMT represents a radically new approach in medicine.
With our Integrated Stress Response (ISR) platform, we develop targeted small-molecule therapeutics that intervene precisely where conventional approaches reach their limits.
Our goal: to fight diseases such as cancer and chronic inflammation in a new way – precise, effective, and pioneering.
Busam vendae eic te et, occum es eliam natus, od quam nem fugia nis il ipsa volo estis vit, odit harumquam a dis estibus.
Alique ressitatint mod quasperibus mil iniet ut fugitas
perersp eriberit, tem. Nestecatio. Itat rem.
Busam vendae eic te et, occum es eliam natus, od quam nem fugia nis il ipsa volo estis vit, odit harumquam a dis estibus alique ressitatint mod quasperibus mil iniet ut fugitas perersp eriberit, tem. Nestecatio. Itat rem.
Busam vendae eic te et, occum es eliam natus, od quam nem fugia nis il ipsa volo estis vit, odit harumquam a dis estibus alique ressitatint mod quasperibus mil iniet ut fugitas perersp eriberit, tem. Nestecatio. Itat rem.
Busam vendae eic te et, occum es eliam natus, od quam nem fugia nis il ipsa volo estis vit, odit harumquam a dis estibus alique ressitatint mod quasperibus mil iniet ut fugitas perersp eriberit, tem. Nestecatio. Itat rem.
Busam vendae eic te et, occum es eliam natus, od quam nem fugia nis il ipsa volo estis vit, odit harumquam a dis estibus.
Alique ressitatint mod quasperibus mil iniet ut fugitas
perersp eriberit, tem. Nestecatio. Itat rem.
Chief Executive Officer & Executive Board
Claus has earned his degree in biochemistry from the University of Tübingen and performed his PhD work in the group of Friedrich Bonhoeffer at the Max-Planck-Institue for Developmental Biology.
He was crucially involved in LION bioscience´s IPO in 2000 raising a European record sum of 220 M Euros. Together with Thomas Hoffmann he co-founded Phenex Pharmaceuticals AG in 2002 which became a very successful biotech company by closing two major asset sales to Janssen (2012) and Gilead (2014) with a total value of more than 600 million US $.
In summer 2020, Claus, together with eight experienced drug discovery scientists and Yves Guillermet from the business side co-founded WMT AG to continue his track record as a serial entrepreneur. Claus serves as the CEO of WMT.
Chief Scientific Officer
Iryna has 20 years’ experience in molecular biology with a focus on metabolism, transcriptional regulation and cancer. She has earned her PhD jointly from the EMBL and the Heidelberg University.
After several years of a postdoc and leading positions in academia (MPI, IMB and EMBL) she transitioned to industry. There she has been responsible for leading projects in the areas of transcriptional regulation, epigenetics and metabolism in oncology and inflammatory diseases.
In 2020, Iryna co-founded WMT AG, where she leads biology research.
Chairman of Supervisory Board
Member of Supervisory Board
Deputy Chairman of the Supervisory Board
Member of Supervisory Board
Member of Supervisory Board
Member of Supervisory Board
WMT AG is a newly established biotech company in beautiful Heidelberg committed to developing novel game changing cancer therapeutics. Our founders team has a depth of 100 (wo)men years of experience in the field of drug discovery and has brought four new drug candidates into clinical development. Get the chance to participate in and contribute to the development of novel cancer therapeutics and apply to the current job openings.
Lorem Ipsum
Bereich Molekularbiologie
Die WMT AG konzentriert sich auf die Entwicklung neuer niedermolekularer Wirkstoffe zur Behandlung von Krebs und Entzündungserkrankungen. Als wachsendes Biotech-Unternehmen in den frühen Jahren bieten wir dir die Möglichkeit, praxisnah mitzuwirken und unser Team aktiv zu verstärken.
Deine Aufgaben
Dein Profil
Wir bieten dir
Interessierte Studierende senden bitte ihr Motivationsschreiben zusammen mit Lebenslauf und Notenübersicht an jobs@wm-therapeutics.com
WMT tests substances from the “Translational Trap” platform for antiviral and antisepsis effects in cellular assays and animal models…
The Swiss foundation supports WMT´s philosophy of uniting excellent drug discovery skills with the idea of making drugs “affordable for the world”
The Düsseldorf-based family office is particularly impressed by the sustainable research and development approach…
WMT AG
Waldhofer Str. 104
69123 Heidelberg
Germany
